|
|
Volumn 73, Issue 1, 2015, Pages 99-105.e1
|
|
A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma
a
|
|
Author keywords
basal cell carcinoma; hedgehog pathway inhibitor; vismodegib
|
|
Indexed keywords
VISMODEGIB;
ANILIDE;
PYRIDINE DERIVATIVE;
ADULT;
AGED;
AGEUSIA;
ALOPECIA;
ARTICLE;
ATRIAL FIBRILLATION;
BASAL CELL CARCINOMA;
BLADDER CANCER;
BRAIN ISCHEMIA;
CANCER CHEMOTHERAPY;
CANCER SURGERY;
CHEMOSURGERY;
CLINICAL ARTICLE;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG SAFETY;
DRUG WITHDRAWAL;
DYSGEUSIA;
EXCISION;
FEMALE;
FOLLOW UP;
HEMORRHOID HEMORRHAGE;
HEPATITIS;
HUMAN;
INTESTINAL BLEEDING;
LIPOSARCOMA;
MALE;
MOHS MICROGRAPHIC SURGERY;
MULTICENTER STUDY;
MULTIMODALITY CANCER THERAPY;
MUSCLE SPASM;
OPEN STUDY;
OUTCOME ASSESSMENT;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
TREATMENT DURATION;
TREATMENT RESPONSE;
CARCINOMA, BASAL CELL;
CLINICAL TRIAL;
COHORT ANALYSIS;
MIDDLE AGED;
SKIN NEOPLASMS;
TREATMENT OUTCOME;
ADULT;
AGED;
ANILIDES;
CARCINOMA, BASAL CELL;
COHORT STUDIES;
FEMALE;
HUMANS;
MALE;
MIDDLE AGED;
PYRIDINES;
SKIN NEOPLASMS;
TREATMENT OUTCOME;
|
|
EID: 84937968152
PISSN: 01909622
EISSN: 10976787
Source Type: Journal
DOI: 10.1016/j.jaad.2015.03.013 Document Type: Article |
|
Times cited : (62)
|
|
References (7)
|
